Vascular brachytherapy with 192Ir after femoropopliteal stent implantation in high-risk patients: Twelve-month follow-up results from the Vienna-5 trial

Radiology

Volumn 236, Issue 1, 2005, Pages 343-351

  Wolfram, Roswitha M ^a   Budinsky, Alexandra C ^a   Pokrajac, Boris ^a   Pötter, Richard ^a   Minar, Erich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CLOPIDOGREL; IRIDIUM 192; IRIDIUM;

ADULT; AGED; ARTERY DISEASE; ARTERY OCCLUSION; ARTERY WALL; ARTICLE; AUSTRIA; BRACHYTHERAPY; CALCULATION; CHI SQUARE TEST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENDOVASCULAR BRACHYTHERAPY; EVALUATION; FEMALE; FEMOROPOPLITEAL ARTERY DISEASE; FOLLOW UP; GAMMA RADIATION; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STENT; STUDENT T TEST; SURVIVAL RATE; CHI SQUARE DISTRIBUTION; FEMORAL ARTERY; GRAFT OCCLUSION; POPLITEAL ARTERY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR;

AGED; ANGIOPLASTY, BALLOON; BRACHYTHERAPY; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; IRIDIUM RADIOISOTOPES; MALE; POPLITEAL ARTERY; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; STENTS;

EID: 20744457365     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2361040696     Document Type: Article

References (28)

1. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty: factors influencing long-term success. Circulation 1991; 83(suppl 2):I70-I80.
2. Johnston KW. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology 1992; 183:767-771.
3. Murray RR Jr, Hewes RC, White RI Jr, et al. Long-segment femoropopliteal stenoses: is angioplasty a boon or a bust? Radiology 1987; 162:473-476.
4. Staab ME, Srivatsa SS, Lerman A, et al. Arterial remodeling after experimental percutaneous injury is highly dependent on adventitial injury and histopathology. Int J Cardiol 1997; 58:31-40.
5. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001; 12:23-31.
6. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol 1997; 20:420-425.
7. Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol 2001; 12:935-942.
8. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? a randomized controlled study. Int Angiol 1999; 18:251-255.
9. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344:250-256.
10. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000; 101:2165-2171.
11. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336:1697-1703.
12. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation 2000; 102:2694-2699.
13. Pokrajac B, Potter R, Maca T, et al. Intraarterial (192)Ir high-dose-rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna-2-trial radiotherapy parameters and risk factors analysis. Int J Radiat Oncol Biol Phys 2000; 48:923-931.
14. Wolfram RM, Pokrajac B, Ahmadi R, et al. Endovascular brachytherapy for prophylaxis against restenosis after long-segment femoropopliteal placement of stents: initial results. Radiology 2001; 220:724-729.
15. Potter R, Van Limbergen E, Dries W, et al. Prescribing, recording, and reporting in endovascular brachytherapy: quality assurance, equipment, personnel and education. Radiother Oncol 2001; 59:339-360.
16. Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral: arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol 1992; 18:433-440.
17. Rutherford RB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. Radiology 1991; 181: 277-281.
18. Krueger K, Landwehr P, Bendel M, et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology 2002; 224:519-528.
19. Waksman R, Laird JR, Jurkovitz CT, et al. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. J Vasc Interv Radiol 2001; 12:915-921.
20. Waksman R, Ajani AE, Pinnow E, et al. Twelve versus 6 months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 2002; 106:776-778.
21. Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation 2001; 103:2332-2335.
22. Bonvini R, Baumgartner I, Do DD, et al. Late acute thrombotic occlusion after endo vascular brachytherapy and stenting of femoropopliteal arteries. J Am Coll Cardiol 2003; 41:409-412.
23. Liermann DD, Bauernsachs R, Schopohl B, Bottcher HD. Five year follow-up after brachytherapy for restenosis in peripheral arteries. Semin Interv Cardiol 1997; 2:133-137.
24. Bottcher HD, Schopohl B, Liermann D, Kollath J, Adamietz IA. Endovascular irradiation: a new method to avoid recurrent stenosis after stent implantation in peripheral arteries-technique and preliminary results. Int J Radiat Oncol Biol Phys 1994; 29:183-186.
25. O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287:618-621.
26. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotetn-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352:87-92.
27. Ajani AE, Waksman R. The WRIST series-what have we learnt? Herz 2002; 27:23-29.
28. Stavropoulos SW, Solomon JA, Soulen MC, Clark TW, Shlansky-Goldberg RD. Use of abciximab during infrainguinal peripheral vascular interventions: initial experience. Radiology 2003; 227:657-661.